Novel potent 5-HT1F receptor agonists: Structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 3060-3071

  Filla, Sandra A ^a,c   Mathes, Brian M ^a   Johnson, Kirk W ^a   Phebus, Lee A ^a   Cohen, Marlene L ^a   Nelson, David L ^a   Zgombick, John M ^b   Erickson, Jon A ^a   Schenck, Kathryn W ^a   Wainscott, David B ^a   Branchek, Theresa A ^b   Schaus, John M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b H LUNDBECK A S   (Denmark)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUORO N [3 (1 METHYLPIPERIDIN 4 YL) 1H PYRROLO[2,3 C]PYRIDIN 5 YL]BENZAMIDE; 4 FLUORO N [3 (1 METHYLPIPERIDIN 4 YL) 1H PYRROLO[3,2 B]PYRIDIN 5 YL]BENZAMIDE; 4 FLUORO N [7 (1 METHYLPIPERIDIN 4 YL) 5H PYRROLO[3,2 D]PYRIMIDIN 2 YL]BENZAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ETHYL N [3 (1 METHYL 4 PIPERIDINYL) 1H PYRROLO[3,2 B]PYRIDIN 5 YL]AMIDE; METHYL N [3 (1 METHYL 4 PIPERIDINYL) 1H PYRROLO[3,2 B]PYRIDIN 5 YL]AMIDE; N [3 (METHYL 4 PIPERIDINYL) 1H PYRROLO[3,2 B]PYRIDIN 5 YL]AMIDE; NEW DRUG; PLASMA PROTEIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DURA MATER; GUINEA PIG; MIGRAINE; MODEL; NEUROGENIC PLASMA PROTEIN EXTRAVASATION MODEL; NONHUMAN; PROTEIN SECRETION; RABBIT; RECEPTOR AFFINITY; SAPHENOUS VEIN; STRUCTURE ACTIVITY RELATION; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD PROTEINS; CELL LINE; MIGRAINE DISORDERS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRIDINES; PYRROLES; RABBITS; RADIOLIGAND ASSAY; RECEPTORS, SEROTONIN; SAPHENOUS VEIN; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGEMINAL NERVE; VASOCONSTRICTION;

EID: 0038798606     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030020m     Document Type: Article

References (44)

1. Plosker, G. L.; McTavish, D. Sumatriptan: A Reappraisal of Its Pharmacology and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache. Drugs 1994, 47, 622-651.
2. 1-like Receptor Agonists and the Pathophysiology of Migraine. Trends Pharmacol. Sci. 1989, 10, 200-204.
3. 1-like Receptor in Dog Isolated Saphenous Vein. Br. J. Pharmacol. 1988, 94, 1123-1132.
4. 1 Agonist, on the Systemic, Pulmonary, and Coronary Circulation. Circulation 1993, 87, 401-405.
5. (a) Ottervanger, J. P.; Stricker, B. H. Cardiovascular Adverse Reactions to Sumatriptan: Cause for Concern? CNS Drugs 1995, 3, 90-98.
6. (b) Hillis, W. S.; MacIntyre, P. D. Sumatriptan and chest pain. Lancet 1993, 341, 1564-1565.
7. (c) Luman, W.; Gray, R. S. Adverse reactions associated with sumatriptan. Lancet 1993, 341, 1091-1092.
8. (a) Humphrey, P. P. A.; Goadsby, P. J. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994, 14, 401-410.
9. (b) Moskowitz, M. A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. 1992, 13, 307-316.
10. Buzzi, M. G.; Moskowitz, M. A. The Trigemino-Vascular System and Migraine. Pathol. Biol. 1992, 40, 313-317.
11. (a) Buzzi, M. G.; Bonamini, M.; Moskowitz, M. A. Neurogenic model of migraine. Cephalalgia 1995, 15, 277-280.
12. (b) Moskowitz, M. A.; Cutrer, F. M.; Lee, W. S.; Waeber, C.; Limmroth, V.; Yu, X. Drug Discovery in Migraine Circa 1995. In Experimental Headache Models; Olesen, J., Moskowitz, M. A., Eds.; Lippincott-Raven Publishers: Philadelphia, PA, 1995; pp 63-73.
13. (a) Hargreaves, R. J.; Williamson, D. J.; Shepheard, S. L. Neurogenic inflammation: relation to novel antimigraine drugs. In Migraine and Headache Pathophysiology; Edvinsson, L., Ed.; Martin Dunitz: London, 1999; pp 95-103.
14. (b) May, A.; Shepheard, S. L.; Knorr, M.; Effert, R.; Wessing, A.; Hargreaves, R. J.; Goadsby, P. J.; Diener, H. C. Retinal plasma extravasation in animals but not humans: implications for the pathophysiology ofmigraine. Brain 1998, 121, 1231-1237.
15. (c) May, A.; Gijsman, H. J.; Wallnöfer, A.; Jones, R.; Diener, H. C.; Ferrari, M. D. Endothelian antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996, 67, 375-378.
16. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport 1997, 8, 2237-2240.
17. (b) Buzzi, M. G.; Moskowitz, M. A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 1990, 99, 202-206.
18. 1F Receptor Agonist in Rabbit Saphenous Vein. J. Pharmacol. Exp. Ther. 1999, 290, 935-939.
19. Cohen, M. L.; Johnson, K. W.; Schenck, K. W.; Phebus, L. A. Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia 1997, 17, 631-638.
20. (a) Bouchelet, I.; Cohen, Z.; Case, B.; Séguéla, P.; Hamel, E. Differential Expression of Sumatriptan-Sensitive 5-Hydroxytryptamine Receptors in Human Trigeminal Ganglia and Cerebral Blood Vessels. Mol. Pharmacol. 1996, 50, 219-223.
21. 1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. 1998, 124, 1345-1354.
22. 1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses. Br. J. Pharmacol. 1999, 127, 405-412.
23. 1F Receptor Agonist Potentially Useful for Migraine Therapy. J. Med. Chem. 2001, 44, 4031-4034.
24. 1F Receptor Agonist. Presented at the 8th Congress of the International Headache Society, Amsterdam, June 10-14, 1997.
25. 1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines. Br. J. Pharmacol. 1998, 124, 283-290.
26. 1F Receptor. Presented at the 26th Annual Meeting of the Society for Neuroscience, Washington, DC, November 1996; Poster 52,812.
27. 1F receptor agonist LY334370. Cephalalgia 1999, 19, 851-858.
28. 1F receptor agonist (SSOFRA) LY334370. Celphalalgia 1999, 19, 318.
29. 1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial. Lancet 2001, 358, 1230-1234.
30. Parker, E. D.; Shive, W. Substituted 2-Picolines Derived from 6-Amino-2-picoline. J. Am. Chem. Soc. 1947, 69, 63-67.
31. Taylor, E. C.; Young, W. B. Pyrrolo[3,2-d]pyrimidine Folate Analogues: "Inverted" Analogues of the Cytotoxic Agent LY231514. J. Org. Chem. 1995, 60, 7947-7952.
32. 1 receptor subtype coupled to the inhibition of adenylate-cyclase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 408-412.
33. 1Dβ. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3630-3634.
34. 1D Receptor Subtype. Mol. Pharmacol. 1991, 40, 1036-1042.
35. 35S]GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur. J. Pharmacol. 1998, 352, 117-124.
36. Johnson, K. W.; Phebus, L. A. A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation. J. Neurosci. Methods 1998, 81, 19-24.
37. MacroModel V6.5. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caulfield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
38. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
39. Structures of ligands studied were obtained from the Cambridge Structural Database (CSD): Cambridge Crystallographic Data Center (CCDC), 12 Union Road, Cambridge CBZ 1EZ, U.K.
40. 2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs. Br. J. Pharmacol. 1996, 117, 283-289.
41. 1F-receptor activation. Br. J. Clin. Pharmacol. 1999, 47, 75-82.
42. Dahlöf, C. Would any acute treatment for migraine demonstrate recurrence? Cephalalgia 1997, 17 (Suppl. 17), 17-20.
43. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8 (Suppl. 7), 1-6.
44. Baumgarten, H. E.; Chien-Fan Su, H. Synthesis of 3- and 5-Nitro-2-picoline and Derivatives. J. Am. Chem. Soc. 1952, 74, 3828-3831.